[Pelvic Inflammatory Diseases: Updated Guidelines for Clinical Practice - Short version]

Area of Science:

• Gynecology
• Infectious Diseases
• Public Health

Background:

• Pelvic inflammatory disease (PID) is a significant cause of gynecological morbidity.
• Timely and accurate diagnosis is crucial for effective management and prevention of long-term complications.
• Existing guidelines require updates to reflect current evidence and best practices.

Purpose of the Study:

• To establish current, evidence-based guidelines for the diagnosis and management of pelvic inflammatory disease (PID).
• To provide clear recommendations for antibiotic treatment and follow-up protocols.
• To emphasize the importance of microbiological investigations and patient education.

Main Methods:

• Comprehensive literature search of Cochrane, PubMed, and Embase databases (1990-2012, updated 2018).
• Inclusion of all relevant French and English reports.
• Application of a level of evidence grading system to inform guideline development.

Main Results:

• PID suspicion criteria: spontaneous pelvic pain with induced adnexal/uterine pain (Grade B).
• Diagnostic tools: Pelvic ultrasonography to exclude tubo-ovarian abscess (TOA) (Grade C); microbiological analysis of endocervical and TOA samples (Grade B).
• Treatment regimens: Uncomplicated PID (ceftriaxone, doxycycline, metronidazole); Complicated PID (IV ceftriaxone, doxycycline, metronidazole); TOA drainage for collections >3cm (Grade B).
• Recommendations: STI follow-up (Grade C), condom use (Grade B), and pre-procedural vaginal sampling (Grade C).

Conclusions:

• Effective PID management relies on reproducible diagnostic methods.
• Antibiotic selection should be tailored to specific sexually transmitted infections (STIs) and vaginal microbiota.
• Regular microbiological follow-up and preventive measures are essential.